[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642746":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":45,"locations":54,"responsibleParty":309,"collaborators":31,"id":311,"slug":312,"hasResults":313,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":31,"eligibilityCriteria":317,"healthyVolunteers":313,"sex":318,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":31,"studyType":324,"phases":325,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":332,"whyStopped":31,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":342},{"fullName":5,"class":6},"Chinese SLE Treatment And Research Group","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Tocilizumab group","EXPERIMENTAL","Tocilizumab will be administered intravenously at a dose of 8 mg\u002Fkg every 4 weeks for 52 weeks in combination with csDMARD.",[13],"Drug: Tocilizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Telitacicept group","Telitacicept will be administered by subcutaneous injection at a dose of 160 mg once weekly for 52 weeks in combination with csDMARD.",[18],"Drug: Telitacicept",{"label":20,"type":21,"description":22,"interventionNames":23},"Methotrexate group","ACTIVE_COMPARATOR","Methotrexate will be administered orally at a dose of 15 mg once weekly for 52 weeks in combination with stable background immunosuppressive therapy.",[24],"Drug: Methotrexate",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Tocilizumab","Tocilizumab will be administered intravenously at a dose of 8 mg\u002Fkg every 4 weeks in addition to stable background csDMARD therapy maintained throughout the study period.",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Telitacicept","Telitacicept will be administered by subcutaneous injection at a dose of 160 mg once weekly in addition to stable background csDMARD therapy maintained throughout the study period",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Methotrexate","Methotrexate will be administered orally at a dose of 15 mg once weekly in addition to stable background csDMARD therapy",[20],[41],{"name":42,"affiliation":43,"role":44},"Xinping Tian","Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",[46,50],{"name":42,"role":47,"phone":48,"phoneExt":31,"email":49},"CONTACT","+86-13691165939","tianxp6@126.com",{"name":51,"role":47,"phone":52,"phoneExt":31,"email":53},"Shangyi Jin","+86-1367049688","jinjinboli@sina.com",[55,71,83,92,100,109,117,129,141,153,165,177,189,201,213,225,237,249,261,273,285,297],{"facility":56,"status":31,"city":57,"state":58,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"The First Affiliated Hospital of Henan University of Science and Technology","Luoyang","Henan","China","CN",{"type":62,"coordinates":63},"Point",[64,65],112.43684,34.67345,{"lat":65,"lon":64},[68,70],{"name":69,"role":47,"phone":31,"phoneExt":31,"email":31},"Xiaofei Shi",{"name":69,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":72,"status":31,"city":73,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Beijing Chao-Yang Hospital, Capital Medical University","Beijing",{"type":62,"coordinates":75},[76,77],116.39723,39.9075,{"lat":77,"lon":76},[80,82],{"name":81,"role":47,"phone":31,"phoneExt":31,"email":31},"Juan Meng",{"name":81,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":84,"status":31,"city":73,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"China-Japan Friendship Hospital",{"type":62,"coordinates":86},[76,77],{"lat":77,"lon":76},[89,91],{"name":90,"role":47,"phone":31,"phoneExt":31,"email":31},"Xin Lu",{"name":90,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":43,"status":31,"city":73,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},{"type":62,"coordinates":94},[76,77],{"lat":77,"lon":76},[97,99],{"name":51,"role":47,"phone":98,"phoneExt":31,"email":53},"+86-13671049688",{"name":42,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":101,"status":31,"city":73,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":102,"geoPoint":104,"contacts":105},"Xuanwu Hospital, Capital Medical University",{"type":62,"coordinates":103},[76,77],{"lat":77,"lon":76},[106,108],{"name":107,"role":47,"phone":31,"phoneExt":31,"email":31},"Yi Zhao",{"name":107,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":110,"status":31,"city":111,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":112,"geoPoint":116,"contacts":31},"China-Japan Union Hospital of Jilin University","Changchun",{"type":62,"coordinates":113},[114,115],125.32278,43.88,{"lat":115,"lon":114},{"facility":118,"status":31,"city":119,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"The First Affiliated Hospital of Army Medical University (Southwest Hospital)","Chongqing",{"type":62,"coordinates":121},[122,123],106.55771,29.56026,{"lat":123,"lon":122},[126,128],{"name":127,"role":47,"phone":31,"phoneExt":31,"email":31},"Qinghua Zou",{"name":127,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":130,"status":31,"city":131,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"The Second Affiliated Hospital of Dalian Medical University","Dalian",{"type":62,"coordinates":133},[134,135],121.60222,38.91222,{"lat":135,"lon":134},[138,140],{"name":139,"role":47,"phone":31,"phoneExt":31,"email":31},"Xiaodan Kong",{"name":139,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":142,"status":31,"city":143,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Handan Central Hospital","Handan",{"type":62,"coordinates":145},[146,147],114.48764,36.60999,{"lat":147,"lon":146},[150,152],{"name":151,"role":47,"phone":31,"phoneExt":31,"email":31},"Xi Liu",{"name":151,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":154,"status":31,"city":155,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"The Second Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou",{"type":62,"coordinates":157},[158,159],120.16142,30.29365,{"lat":159,"lon":158},[162,164],{"name":163,"role":47,"phone":31,"phoneExt":31,"email":31},"Jing Xue",{"name":163,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":166,"status":31,"city":167,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"The First Affiliated Hospital of Anhui Medical University","Hefei",{"type":62,"coordinates":169},[170,171],117.28083,31.86389,{"lat":171,"lon":170},[174,176],{"name":175,"role":47,"phone":31,"phoneExt":31,"email":31},"Shengqian Xu",{"name":175,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":178,"status":31,"city":179,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Affiliated Hospital of Inner Mongolia Medical University","Hohhot",{"type":62,"coordinates":181},[182,183],111.65222,40.81056,{"lat":183,"lon":182},[186,188],{"name":187,"role":47,"phone":31,"phoneExt":31,"email":31},"Hongbin Li",{"name":187,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":190,"status":31,"city":191,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Jiujiang No. 1 People's Hospital","Jiujiang",{"type":62,"coordinates":193},[194,195],116.00206,29.70475,{"lat":195,"lon":194},[198,200],{"name":199,"role":47,"phone":31,"phoneExt":31,"email":31},"Ju Liu",{"name":199,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":202,"status":31,"city":203,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"The Second Hospital of Lanzhou University","Lanzhou",{"type":62,"coordinates":205},[206,207],103.83987,36.05701,{"lat":207,"lon":206},[210,212],{"name":211,"role":47,"phone":31,"phoneExt":31,"email":31},"Haili Shen",{"name":211,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":214,"status":31,"city":215,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"The Second Affiliated Hospital of Nanchang University","Nanchang",{"type":62,"coordinates":217},[218,219],115.85306,28.68396,{"lat":219,"lon":218},[222,224],{"name":223,"role":47,"phone":31,"phoneExt":31,"email":31},"Xinwang Duan",{"name":223,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":226,"status":31,"city":227,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"The First Affiliated Hospital of Nanjing Medical University","Nanjing",{"type":62,"coordinates":229},[230,231],118.77778,32.06167,{"lat":231,"lon":230},[234,236],{"name":235,"role":47,"phone":31,"phoneExt":31,"email":31},"Wenfeng Tan",{"name":235,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":238,"status":31,"city":239,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":240,"geoPoint":244,"contacts":245},"The First Affiliated Hospital of Guangxi Medical University","Nanning",{"type":62,"coordinates":241},[242,243],108.31667,22.81667,{"lat":243,"lon":242},[246,248],{"name":247,"role":47,"phone":31,"phoneExt":31,"email":31},"Ling Lei",{"name":247,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":250,"status":31,"city":251,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":252,"geoPoint":256,"contacts":257},"Shanxi Bethune Hospital","Taiyuan",{"type":62,"coordinates":253},[254,255],112.56028,37.86944,{"lat":255,"lon":254},[258,260],{"name":259,"role":47,"phone":31,"phoneExt":31,"email":31},"Liyun Zhang",{"name":259,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":262,"status":31,"city":263,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":264,"geoPoint":268,"contacts":269},"The First Affiliated Hospital of Xinjiang Medical University","Ürümqi",{"type":62,"coordinates":265},[266,267],87.60046,43.80096,{"lat":267,"lon":266},[270,272],{"name":271,"role":47,"phone":31,"phoneExt":31,"email":31},"Li Luo",{"name":271,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":274,"status":31,"city":275,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":276,"geoPoint":280,"contacts":281},"Xingyi People's Hospital","Xingyi",{"type":62,"coordinates":277},[278,279],104.90639,25.09617,{"lat":279,"lon":278},[282,284],{"name":283,"role":47,"phone":31,"phoneExt":31,"email":31},"Houli Liao",{"name":283,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":286,"status":31,"city":287,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":288,"geoPoint":292,"contacts":293},"Affiliated Hospital of Yan'an University","Yan’an",{"type":62,"coordinates":289},[290,291],109.49167,36.59889,{"lat":291,"lon":290},[294,296],{"name":295,"role":47,"phone":31,"phoneExt":31,"email":31},"Yuhong Liu",{"name":295,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":298,"status":31,"city":299,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":300,"geoPoint":304,"contacts":305},"People's Hospital of Ningxia Hui Autonomous Region","Yinchuan",{"type":62,"coordinates":301},[302,303],106.27306,38.46806,{"lat":303,"lon":302},[306,308],{"name":307,"role":47,"phone":31,"phoneExt":31,"email":31},"Donggeng Guo",{"name":307,"role":44,"phone":31,"phoneExt":31,"email":31},{"type":310,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100642746","phase-4-treatment-strategy-for-patients-with-ra-ild-100642746",false,"NCT07643038","Treatment Strategy for Patients With RA-ILD","Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease","Inclusion Criteria:\n\n* Fulfillment of the 2010 ACR\u002FEULAR classification criteria for RA.\n* HRCT findings consistent with interstitial lung disease (ILD), including ground-glass opacities, reticular abnormalities, fibrotic linear opacities, traction bronchiectasis, or other compatible features, with pulmonary infection, cardiogenic pulmonary edema, and alveolar hemorrhage excluded. The extent of ILD involvement must be ≥20% on HRCT, as assessed by central review.\n* Pulmonary function impairment defined as forced vital capacity (FVC) \\\u003C80% of predicted and\u002For diffusing capacity of the lung for carbon monoxide (DLCO) \\\u003C70% of predicted.\n* Participants receiving glucocorticoids prior to enrollment must be on a stable dose of prednisone ≤10 mg\u002Fday (or equivalent) for at least 4 weeks before baseline.\n* Participants receiving a csDMARD prior to enrollment must be on a stable regimen for at least 4 weeks before baseline.\n* Able and willing to provide written informed consent and comply with study requirements, including scheduled visits and follow-up assessments.\n\nExclusion Criteria:\n\n* Presence of other autoimmune diseases.\n* Presence of severe, uncontrolled clinically significant organ dysfunction or other medical conditions that, in the investigator's judgment, would place the participant at unacceptable risk.\n* History of malignancy within 5 years prior to screening.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study period.\n* Known hypersensitivity to tocilizumab, telitacicept, methotrexate, or any of their excipients.\n* Active hepatitis B or C virus infection, active tuberculosis, active herpes zoster infection, or a history of serious infection within 12 weeks prior to study treatment initiation (defined as an infection requiring hospitalization or intravenous antimicrobial therapy).\n* Severe hypoalbuminemia or serum immunoglobulin G (IgG) level \\\u003C6 g\u002FL.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × the upper limit of normal (ULN), total bilirubin \\>1.5 × ULN, or creatinine clearance (CrCl) \\\u003C60 mL\u002Fmin.\n* Participation in another interventional clinical trial within 4 weeks prior to screening.\n* Inability to adequately perform pulmonary function testing or other study-related assessments.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.","ALL","18 Years","80 Years",{"count":322,"type":323},204,"ESTIMATED","INTERVENTIONAL",[326],"PHASE4","This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.",[329],"Rheumatoid Arthritis Associated Interstitial Lung Disease",[331,33,28],"randomized controlled trial","NOT_YET_RECRUITING","2026-06-07",{"date":335,"type":336},"2026-06-11","ACTUAL",{"date":338,"type":323},"2026-07-01",{"date":340,"type":323},"2029-07-31",{"name":5,"class":6},22]